Anzeige
Mehr »
Login
Donnerstag, 21.11.2024 Börsentäglich über 12.000 News von 677 internationalen Medien
Von Solarenergie zu digitalen Assets: Die Strategie hinter der 75-Prozent-Rallye
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3E2GA | ISIN: BMG0360L1349 | Ticker-Symbol:
NASDAQ
20.11.24
17:34 Uhr
0,430 US-Dollar
0,000
0,00 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ALTAMIRA THERAPEUTICS LTD Chart 1 Jahr
5-Tage-Chart
ALTAMIRA THERAPEUTICS LTD 5-Tage-Chart

Aktuelle News zur ALTAMIRA THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
04.10.Altamira Therapeutics receives Nasdaq non-compliance letter6
04.10.Altamira Therapeutics Ltd: Altamira Therapeutics Provides Update on Nasdaq Listing124Hamilton, Bermuda, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq:CYTO) today announced that it received on September 30, 2024, a letter from the...
► Artikel lesen
04.10.Altamira Therapeutics Ltd. - 6-K, Report of foreign issuer5
ALTAMIRA THERAPEUTICS Aktie jetzt für 0€ handeln
27.09.Altamira Therapeutics Ltd: Altamira Therapeutics Announces Extended ISO 13485 Quality Management System Certification for Bentrio Nasal Spray1
25.09.Earnings call: Altamira Therapeutics focuses on RNA delivery growth2
24.09.Altamira Therapeutics reports 1H results2
24.09.Altamira Therapeutics Ltd: Altamira Therapeutics Provides Business Update and First Half 2024 Financial Results107Hamilton, Bermuda, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Company to host conference call today at 8.30 a.m. ETContinued progress within core activities in RNA delivery, supported by move into new...
► Artikel lesen
20.09.Altamira Therapeutics Ltd: Altamira Therapeutics to Host First Half 2024 Financial Results and Business Update Call on September 24, 20242
19.09.Altamira Therapeutics Ltd. - 6-K, Report of foreign issuer1
19.09.Altamira Therapeutics Ltd: Altamira Therapeutics Announces Closing of up to $12.0 Million Public Offering1
17.09.Altamira Therapeutics kündigt öffentliches Angebot von 4 Millionen US-Dollar an1
17.09.Altamira Therapeutics announces $4 million public offering2
17.09.Altamira Therapeutics prices up to $12M public offering1
17.09.Altamira Therapeutics Ltd: Altamira Therapeutics Announces Pricing of up to $12.0 Million Public Offering1
16.09.Altamira Therapeutics Ltd. - F-1/A, Registration statement for certain foreign private issuers1
16.09.Altamira Therapeutics Ltd: Altamira Therapeutics Announces Expansion of Bentrio License and Distribution Agreement with Nuance Pharma in East and South East Asia93Hamilton, Bermuda, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Nuance Pharma successfully launched Bentrio® nasal spray for protection against airborne particles in Hong Kong and filed request for marketing...
► Artikel lesen
03.09.Altamira Therapeutics Ltd: Altamira Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference September 9-112
23.08.Altamira Therapeutics Ltd: Altamira Therapeutics Announces Extension of Bentrio Distribution Agreement with Pharma Nordic to Include Sweden and Denmark84Hamilton, Bermuda, Aug. 23, 2024 (GLOBE NEWSWIRE) -- Successful launch of Bentrio by Pharma Nordic AS in Norway in 2024Exclusive distribution agreement extended to also include Sweden and Denmark...
► Artikel lesen
22.08.Altamira Therapeutics files mixed shelf offering1
22.08.Altamira Therapeutics Ltd. - F-1, Registration statement for certain foreign private issuers2
Seite:  Weiter >>
32 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1